Evidence map›Paper›PMID 36032089›Full record

ArticleFrontiers in immunology2022

Penta-o-galloyl-beta-d-Glucose (PGG) inhibits inflammation in human rheumatoid arthritis synovial fibroblasts and rat adjuvant-induced arthritis model.

Sadiq Umar, Anil K Singh, Mukesh Chourasia, Stephanie M Rasmussen, Jeffrey H Ruth, Salahuddin Ahmed

Open access · goldAbstract read
In one paragraph

Article in Frontiers in immunology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
1.3field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 16 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Frontiers in immunology · 2025
    Review
  7. Article
  8. Review
  9. Review
  10. Review
  11. Article
  12. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 2 countries.

Sadiq UmarDepartment of Pharmaceutical Sciences, Washington State University College of Pharmacy and Pharmaceutical Sciences, Spokane, WA, United States.
Anil K SinghDepartment of Pharmaceutical Sciences, Washington State University College of Pharmacy and Pharmaceutical Sciences, Spokane, WA, United States.
Mukesh ChourasiaCenter for Computational Biology and Bioinformatics, Amity Institute of Biotechnology, Amity University Uttar Pradesh, Noida, India.
Stephanie M RasmussenDivision of Rheumatology, University of Michigan Medical School, Ann Arbor, MI, United States.
Jeffrey H RuthDivision of Rheumatology, University of Michigan Medical School, Ann Arbor, MI, United States.
Salahuddin AhmedDepartment of Pharmaceutical Sciences, Washington State University College of Pharmacy and Pharmaceutical Sciences, Spokane, WA, United States.
Washington State University Spokane · USUniversity of Michigan–Ann Arbor · USAmity University · IN

Funding

MicroRNA-based therapy for rheumatoid arthritisR01AR072615 · NIAMS · WASHINGTON STATE UNIVERSITY · PI AHMED, SALAH-UDDIN · 2018 to 2022
$1.9M
Regulation of IL-6 mediated inflammation and tissue destruction by EGCGR01AR063104 · NIAMS · WASHINGTON STATE UNIVERSITY · PI AHMED, SALAH-UDDIN · 2013 to 2017
$1.7M
NIAMS NIH HHS R01 AR063104NIAMS NIH HHS R01 AR072615
6 · The paper itself

Abstract

O-GlcNAcylation is a reversible post-translational modification that regulates numerous cellular processes, including embryonic development as well as immune responses. However, its role in inflammation remains ambiguous. This study was designed to examine the role of O-GlcNAcylation in rheumatoid arthritis (RA) and its regulation using human RA patient-derived synovial fibroblasts (RASFs). The efficacy of penta-O-galloyl-beta-D-glucose (PGG), a potent anti-inflammatory molecule, in regulating inflammatory processes in human RASFs was also evaluated. Human synovial tissues and RASFs exhibited higher expression of O-GlcNAcylation compared to their non-diseased counterparts. Pretreatment of RASFs with Thiamet G, an inhibitor of O-GlcNAcase, markedly increased the O-GlcNAc-modified proteins and concomitantly inhibited the IL-1β-induced IL-6 and IL-8 production in human RASFs

Indexed as

Arthritis, ExperimentalArthritis, RheumatoidGlucoseAnimalsFibroblastsHumansInflammationInterleukin-6Interleukin-8Molecular Docking SimulationRatsSynovial MembraneGlucoseInterleukin-6Interleukin-8O-GlcNAcylationPenta-o-galloyl-beta-D-glucose (pgg)post-translational modificationrheumatoid arthritissynovial fibroblastsTGF beta-activated kinase 1 (TAK1)

Identifiers

PMID36032089
PMCPMC9400595
OpenAlexW4293779429

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.